M0 acute non lymphocytic leukemia (M0-ANLL)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Published in Atlas Database: December 1999
Online updated version: http://AtlasGeneticsOncology.org/Anomalies/M0ANLLID1057.html
DOI: 10.4267/2042/37564

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 1999 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity
Alias: Minimally differentiated acute myeloid leukemia

Clinics and pathology

Epidemiology
Rare: 3-5% of ANLL; med age 45 years; 20% are children; unbalanced sex ratio in the adults: 1.6 M/1 F, p<0.01.

Cytology
Cytochemistry: negative for myeloperoxidase, positive for myeloid markers and negative for specific markers of the lymphoid or megakaryocytic lineages; immunophenotype: CD34+, HLA-DR+, CD117+ (corresponding to c-KIT), TdT+, CD7+.

Prognosis
Poor: CR in 50% of cases, med survival: 8 months.

Cytogenetics

Cytogenetics morphological
High percentage of complex (20%) and unbalanced karyotypes; partial or complete monosomy (5/del(5q), -7/del(7q), or rearrangements of chromosome 5 and/or 7 in 15-20%; chromosome 11 rearrangements (11q23 in particular), and chromosome 8 involvement (+8) in 10-15%; t(9;22)(q34;q11) in 5%; normal karyotype in 20%.

References


This article should be referenced as such: